Julie M. Vose, MD, MBA

Neumann M. and Mildred E. Harris Professor

University of Nebraska Medical Center

Julie M. Vose, MD is the Neumann M. and Mildred E. Harris Professor and Chief in the Division of Oncology/Hematology at the University of Nebraska Medical Center in Omaha, Nebraska. Dr Vose received her medical degree, completed her residency in Internal Medicine, served as Chief Resident, and completed a Fellowship in Hematology/Oncology at the University of Nebraska Medical Center. Dr Vose also completed a sabbatical at Stanford University. She also completed an MBA in Health Administration through the University of Colorado Business School.

Dr Vose has focused her career on translational research for improvement in the therapy of non-Hodgkin’s lymphoma (NHL) and Hodgkin lymphoma (HL) by developing a focused translational research program evaluating novel therapies such as radiolabeled monoclonal antibodies, idiotype vaccine therapies, pathway directed agents and stem cell transplantation. Dr Vose has been recognized for her NHL research on a national and international level through research awards and invited lectureships worldwide. In addition, her funding record and publications in NHL therapy and transplantation research have added substantially to the research and knowledge base for the therapy of lymphoma. She is currently the Co-Chair for the National Cancer Institute Lymphoma Sub-Committee, a member of the FDA Oncologic Drug Advisory Committee, and 2014-15 President elect for the American Society of Clinical Oncology (ASCO).

New Directions in the Management of Mantle Cell Lymphoma

James O. Armitage, MD

The Joe Shapiro Professor of Medicine

University of Nebraska Medical Center

Dr. James O. Armitage, a graduate of the University of Nebraska Medical Center, completed his internship and residency in internal medicine at Nebraska, a fellowship in hematology oncology at the University of Iowa and a brief stint in private practice in Omaha. He developed and directed the Bone Marrow Transplant program at the University of Iowa and later at the University of Nebraska. At Nebraska he served as Vice-Chair of Internal Medicine, Chief of the Section of Oncology and Hematology, Chair of the Department of Internal Medicine, and Dean of the College of Medicine. He currently is The Joe Shapiro Professor of Medicine at the University of Nebraska Medical Center. Dr. Armitage is board certified in internal medicine, medical oncology, and hematology, and a Fellow of both the American and Royal College of Physicians and of the American Association for the Advancement of Sciences. He has served on many national/international oncology committees including the United States National Cancer Advisory Board and the French National Cancer Advisory Board. He is past president of both the American Society of Clinical Oncology and the American Society of Blood and Marrow Transplantation. He has served on the Scientific Committee of the International Congress on Anti-Cancer Treatment in Paris, France, the International Symposium on Hodgkin Lymphoma in Cologne, Germany and the International Conference on Malignant Lymphoma in Lugano, Switzerland.

He has numerous honors including the Claude Jacquillat Award for achievement in Clinical Oncology from Paris, the San Salvatore Foundation Research Award from Lugano, Switzerland, the Richard and Hinda Rosenthal Foundation Award from the American Association of Cancer Research, the Heath Memorial Award from the University of Texas MD Anderson Cancer Center, the Robert A. Kyle Award from the Mayo Clinic, and election to the Association of American Physicians. Dr. Armitage has published more than 500 papers, written 110 chapters and is co-editor of 27 books. He and his wife, Nancy, have four children and ten grandchildren.

New Directions in the Management of Mantle Cell Lymphoma

Andrew Zelenetz, MD, PhD

Vice Chair, Department of Medicine

Professor of Medicine, Weill-Cornell Medical College

Andrew D. Zelenetz, MD, PhD is the Vice Chair, Medical Informatics in the Department of Medicine at Memorial Sloan-Kettering Cancer Center in New York. Prior to that, he had held the position of Chief, Lymphoma Service in the Division of Hematology/Oncology at MSKCC from 1994-January, 2013. He is also Professor of Medicine at Weill Medical College of Cornell University.
He has helped develop a number of the agents now approved to treat lymphoma — including 131I-tosituomab/tositumomab, bortezomib, and pralatrexate — and through clinical studies he is evaluating the benefits of novel combinations of agents. In another area of research he is working to improve the prognostic value of patients’ pathology specimens using computer-aided image analysis. He has published more than 100 papers on lymphoma research in journals such as Blood, Journal of Clinical Oncology and Clinical Cancer Research.
Dr. Zelenetz received his BA from Harvard College, his PhD from Harvard University’s Graduate School of Arts and Sciences, Division of Medical Sciences and his MD from Harvard Medical School. Both his internship and residency in medicine were completed at Stanford University Medical Center as well as a clinical fellowship and research fellowship in oncology.
Dr. Zelenetz is a member of the American Society of Hematology, the American Society of Clinical Oncology and the American College of Physicians. He participates in various committees: he is Vice Chairperson of the Cancer and Leukemia Group B Lymphoma Core Committee, Chair of the NCCN Non-Hodgkin’s Lymphoma Panel, Board Member of the Leukemia and Lymphoma Society and member of the Lymphoma Research Foundation Scientific Advisory Board. He has been the recipient of the Memorial Sloan Kettering Fellowship Teaching Excellence Award multiple times and has received the Rodger Winn Award from the National Comprehensive Cancer Network in 2012.

Managing Diffuse Large B-cell Lymphoma (DLBCL): A Case-based Approach to Treatment Selection

Evaluating New & Emerging Treatment Options for Non-Hodgkin Lymphoma (NHL)

Andre Goy, MD, MS

Chairman and Director and Chief of Lymphoma

John Theurer Cancer Center, at Hackensack University Medical Center

Andre Goy, M.D., M.S., is an internationally renowned clinician and researcher of all types of lymphoma, including Hodgkin’s disease, non-Hodgkin’s lymphoma, and HIV-associated lymphoma. As chief of John Theurer Cancer Center’s Division of Lymphoma, he leads New Jersey’s largest program for research, treatment and management of lymphoma. Dr. Goy has trained and/or worked at some of the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, M.D. Anderson Cancer Center, University Hospitals Group of Paris and The Pasteur Institute.
Dr. Goy was instrumental in developing the John Theurer Cancer Center’s Tissue Bank, where samples of cells, tissue, and other anatomical structures are stored and analyzed for research purposes. The Tumor Bank has received more than 1,600 patient consents since it launched.
Dr. Goy is widely-known for his work showing the first evidence of activity of bortezomib in mantle cell lymphoma and then as co-principal investigator on the PINNACLE trial, which led to the Food & Drug Administration’s approval of VELCADE® (bortezomib) for relapsed / refractory mantle cell lymphoma patients in 2006. He also took part in the original pilot study for RITUXAN® (rituximab), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders.
Dr. Goy’s research centers on developing novel targeted therapies for lymphoma and developing biomarkers for lymphoma. He has been invited to speak and teach around the world, and his research has been published extensively. He is a journal reviewer for eight medical publications that include: Blood, Clinical Cancer Research and the Journal of Clinical Oncology.

Managing Diffuse Large B-cell Lymphoma (DLBCL): A Case-based Approach to Treatment Selection

Evaluating New & Emerging Treatment Options for Non-Hodgkin Lymphoma (NHL)

Kenneth Anderson, MD

Kraft Family Professor of Medicine

Harvard Medical School

Dr. Anderson is the Kraft Family Professor of Medicine at Harvard Medical School as well as Director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute. He is a Doris Duke Distinguished Clinical Research Scientist and American Cancer Society Clinical Research Professor. After graduating from Johns Hopkins Medical School, he trained in internal medicine at John’s Hopkins Hospital, and then completed hematology, medical oncology, and tumor immunology training at the Dana-Farber Cancer Institute. Over the last three decades, he has focused his laboratory and clinical research studies on multiple myeloma. He has developed laboratory and animal models of the tumor in it is microenvironment which have allowed for both identification of novel targets and validation of novel targeted therapies, and has then rapidly translated these studies to clinical trials culminating in FDA approval of novel targeted therapies. His paradigm for identifying and validating targets in the tumor cell and its milieu has transformed myeloma therapy and markedly improved patient outcome. He is the recipient of many scientific and humanitarian awards including the International Myeloma Workshop Waldenstrom’s Award in 2003, the International Myeloma Foundation Robert A. Kyle Lifetime Achievement Award in 2005, the American Association for Cancer Research Joseph H. Burchenal Award in 2007, and the American Society of Hematology William Dameshek Prize in 2008. He was elected into the Johns Hopkins Society of Scholars in 2009, the Institute of Medicine of the National Academy of Sciences in 2010, and the Royal College of Physicians and of Pathologists (UK) in 2010. In 2011 he received the American Society of Clinical Oncology David A. Karnofsky Award and the Hope Funds for Cancer Research Award of Excellence in Clinical Research, and in 2012 received the Ron Burton Humanitarian Award, the Harvard Medical School Warren Alpert Foundation Prize, and the American Cancer Society Medal of Honor.

Integrating New Therapies into the Treatment of Newly Diagnosed MM

Controversies in the Management of Relapsed/Refractory MM

Philip McCarthy, MD

Professor of Oncology

Roswell Park Cancer Institute

Dr. McCarthy is the Director of the Blood and Marrow Transplantation (BMT) Program at Roswell Park Cancer Institute (RPCI) and a Professor of Oncology. Dr. McCarthy has been a BMT Physician and Hematologist/Oncologist since finishing fellowship training in 1989. He has been the BMT Director at RPCI since 1997. He is a member of the Cancer and Leukemia Group B (CALGB) cooperative clinical trials group, the Center for Institutional Research on Blood and Marrow Transplantation (CIBMTR) as well as a member of the editorial boards of two BMT journals. He has been a clinical investigator in oncology, particular BMT, for more than 20 years. He has served as chair, or co-chair, of several clinical trials, including CALGB 100104, a phase III clinical trial evaluating lenalidomide maintenance after autologous hematopoietic cell transplant (HCT) for multiple myeloma. He is a member of the protocol team for the ongoing BMT Clinical Trials Network (CTN) study: A Trial Single Autologous Transplant with or without RVD Consolidation versus Tandem Transplant and Maintenance Therapy for Patients with Multiple Myeloma. Dr. McCarthy is a member of the American Society of Hematology and the American Society of Clinical Oncology. His research interests are devoted to developing novel myeloablative and non-myeloablative autologous and allogeneic BMT treatments of hematologic disorders that will lead to improved patient outcomes and decreased toxicity.

Integrating New Therapies into the Treatment of Newly Diagnosed MM

Controversies in the Management of Relapsed/Refractory MM

Judd W Moul, MD

Director, Duke Prostate Center

Duke University Medical Center

Dr Judd W. Moul is Professor and Chief of the Division of Urologic Surgery and Director of the Duke Prostate Center at Duke University Medical Center. Prior to joining Duke, he was Professor of Surgery at the Uniformed Services University of the Health Sciences (USUHS) in Bethesda, Maryland, and an attending Urologic Oncologist at the Walter Reed Army Medical Center (WRAMC) in Washington, DC. In addition, he was Director of the Center for Prostate Disease Research, a Congress-mandated research program of the Department of Defense based at USUHS and WRAMC. Dr Moul completed his Urologic Oncology Fellowship at Duke University and graduated summa cum laude from Pennsylvania State University. He earned his medical degree from Jefferson Medical College.
Dr Moul currently serves on the editorial boards of Urology, Brazilian Journal of Urology, and World Journal of Robotic Surgery, and is Co-Editor of Prostate Cancer and Prostatic Diseases. He has published over 500 medical and scientific manuscripts and book chapters and has lectured at national and international meetings.
Honors received have included the 1995 American Medical Association Young Physicians Section Community Service Award for his national involvement in prostate cancer patient support groups, the 1996 Sir Henry Welcome Research Medal and Prize from the Association of Military Surgeons of the United States, and selection as a 1994 Fellow for the American Urological Association/European Association of Urology International Academic Exchange Program. In 2006, Dr. Moul was selected as Chairman of the newly founded American Urological Association Foundation Education Council.

Clinical Decision Making in Treating Patients With mCRPC Who Have Progressed on ADT

Forgot Password Click Here to Register